Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
177
-
Total 13F shares, excl. options
-
71.7M
-
Shares change
-
+734K
-
Total reported value, excl. options
-
$2.89B
-
Value change
-
+$18.6M
-
Put/Call ratio
-
0.34
-
Number of buys
-
81
-
Number of sells
-
-87
-
Price
-
$40.23
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q4 2024
214 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q4 2024.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 177 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.7M shares
.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (6.87M shares), BAKER BROS. ADVISORS LP (6M shares), WELLINGTON MANAGEMENT GROUP LLP (5.31M shares), BVF INC/IL (5.16M shares), Avoro Capital Advisors LLC (5.15M shares), Atlas Venture Life Science Advisors, LLC (4.9M shares), VANGUARD GROUP INC (4.89M shares), FMR LLC (4.83M shares), BlackRock, Inc. (4.36M shares), and Siren, L.L.C. (2.97M shares).
This table shows the top 177 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.